Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-02
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • SB202190 br Overall our results suggest

    2022-08-15


    Overall, our results suggest a clinically significant rate of actionable cancer predisposition gene mutations and LS gene mutations among EC patients. Further study is needed to determine whether these muta-tions could be detected with IHC analysis of endometrial tumors. These findings suggest that somatic testing for an expanded panel of cancer predisposition gene mutations could identify patients in which germline testing is warranted.
    Author contributions
    Beverly Long: study design, manuscript writing, data preparation, data interpretation, table and figure preparation.
    Jenna Lilyquist: methods section writing, data preparation, data analysis and SB202190 calling, manuscript editing, data interpretation.
    Amy Weaver: statistics calculation and analysis, editing of manu-script, table preparation.
    Chunling Hu: sample preparation, DNA extraction.
    Rohan Gnanaolivu: DNA sequencing and bioinformatic analysis.
    Kun Y. Lee: sample preparation, DNA extraction.
    Steven N. Hart: DNA sequencing and analysis, bioinformatics/ statistics.
    Eric C. Polley: DNA sequencing and analysis, bioinformatics/ statistics.
    Jamie N. Bakkum-Gamez: study design, data interpretation, editing of manuscript.
    Fergus J. Couch: study design, data interpretation, supervision of DNA sequencing and analysis, editing of manuscript.
    Sean C. Dowdy: study design, data interpretation, supervision of manuscript preparation/writing, editing of manuscript.
    Appendix A. Supplementary data
    Supplementary data to this article can be found online at https://doi.
    References
    [1] J.V. Bokhman, Two pathogenetic types of endometrial carcinoma, Gynecol. Oncol. 15
    B. Dougherty, J. Barrett, J.R. Dry, VarDict: a novel and versatile variant caller for the next-generation sequencing in cancer research, Nucleic Acids Res. 44 (11) (2016) e108.
    [24] SB202190 American Gastroenterology Association, American Gastroenterology Association medical position statement: hereditary colorectal cancer and genetic testing, Gas-troenterology 121 (2001) 195. [25] A.S. Bruegl, B. Djordjevic, B. Batte, M. Daniels, B. Fellman, D. Urbauer, R. Luthra, C. Sun, K.H. Lu, R.R. Broaddus, Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer, Cancer Prev. Res. (Phila.) 7 (7) (2014) 686–697.
    Cancer Symptom Recognition and Anticipated Delays in Seeking Care Among U.S. Adults
    Introduction: Early stage diagnosis strongly predicts cancer survival. Recognition of potential symptoms of cancer may improve survival by reducing time to seeking care.
    Methods: Telephone interviews with a population-representative sample of English-speaking adults (aged ≥50 years) in the U.S. (N=1,425) were conducted in 2014 using an instrument adapted from the International Cancer Benchmarking Partnership Awareness and Beliefs about Cancer sur-vey. Anticipated time to seeking care for four cancer symptoms (persistent cough, rectal bleeding, mole changes, and breast changes) was assessed, and delay was defined as waiting >2 weeks. Recog-nition of symptoms as potential cancer signs was assessed dichotomously. Multivariate logistic regression models were used to assess associations between symptom recognition and anticipated delay, adjusting for demographics, cancer experience, self-reported health, and healthcare access. Analyses were weighted and conducted in 2017.
    Conclusions: Lack of symptom recognition was associated with anticipated delay in seeking care for some cancer symptoms. Differences in recognition and delays by symptom could be driven partly by screening messaging or by ambiguity and functional impact of each symptom.